GlassScriptPhysician profile
Ambereen M Jan
NPI 1619929932
$4,575.25
in general payments reported to CMS, 2019-2025
28 companies · $928 in 2025
The $928 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2020: $282 · 2021: $382 · 2022: $661 · 2023: $903 · 2024: $910 · 2025: $928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,716 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,716.35 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,191.23 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $512.96 | 2019-2025 | Jynarque, Voyxact |
| Ani Pharmaceuticals, INC. | $327.36 | 2022-2025 | Purified Cortrophin Gel |
| Amgen INC. | $276.47 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Vifor Pharma, INC. | $272.96 | 2019-2025 | Veltassa, Korsuva |
| Akebia Therapeutics INC | $182.76 | 2022-2025 | Vafseo, Auryxia |
| Lilly USA, LLC | $173.08 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $161.05 | 2024-2025 | |
| Zoll Respicardia, INC. | $148.43 | 2023 | Remede System |
| Bayer Healthcare Pharmaceuticals INC. | $147.71 | 2022-2025 | |
| Glaxosmithkline, LLC. | $137.02 | 2022-2024 | Benlysta, Jesduvroq |
| Amarin Pharma, INC. | $120.82 | 2019 | |
| Medtronic, INC. | $117.14 | 2022 | |
| Novo Nordisk INC | $106.92 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Opko Pharmaceuticals, LLC | $90.15 | 2020-2025 | Rayaldee |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $85.35 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $81.71 | 2022-2025 | Acthar |
| Travere Therapeutics, INC. | $79.19 | 2024-2025 | Filspari |
| Fresenius USA Marketing, INC. | $78.24 | 2021-2025 | Velphoro |
| Calliditas Therapeutics US INC. | $49.81 | 2024-2025 | Tarpeyo |
| Ardelyx, INC. | $45.83 | 2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $38.79 | 2024-2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $34.09 | 2022 | |
| Kyowa Kirin, INC. | $28.47 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.93 | 2025 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.67 | 2021 | |
| Genzyme Corporation | $20.61 | 2024 | |
| Scpharmaceuticals INC. | $18.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ambereen Jan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.